Literature DB >> 26599515

Peptide triazole inactivators of HIV-1: how do they work and what is their potential?

Irwin Chaiken1, Adel A Rashad1.   

Abstract

Entities:  

Keywords:  AIDS; HIV-1; cell entry; envelope protein antagonism; infection inhibition; macrocycle; peptidomimetics; virus inactivation

Mesh：

Substances：

Year:  2015        PMID： 26599515      PMCID： PMC4939406          DOI： 10.4155/fmc.15.152

Source DB:  PubMed          Journal:  Future Med Chem        ISSN： 1756-8919            Impact factor:   3.808


× No keyword cloud information.
  24 in total

1.  Mode of action for linear peptide inhibitors of HIV-1 gp120 interactions.

Authors:  Alyssa C Biorn; Simon Cocklin; Navid Madani; Zhihai Si; Tijana Ivanovic; James Samanen; Donald I Van Ryk; Ralph Pantophlet; Dennis R Burton; Ernesto Freire; Joseph Sodroski; Irwin M Chaiken
Journal:  Biochemistry       Date:  2004-02-24       Impact factor: 3.162

2.  The critical need for alternative antiretroviral formulations, and obstacles to their development.

Authors:  Susan Swindells; Charles Flexner; Courtney V Fletcher; Jeffrey M Jacobson
Journal:  J Infect Dis       Date:  2011-07-25       Impact factor: 5.226

3.  Peptide ligands to human immunodeficiency virus type 1 gp120 identified from phage display libraries.

Authors:  M Ferrer; S C Harrison
Journal:  J Virol       Date:  1999-07       Impact factor: 5.103

4.  Cell-free HIV-1 virucidal action by modified peptide triazole inhibitors of Env gp120.

Authors:  Arangassery R Bastian; Karyn McFadden; Caitlin Duffy; Srivats Rajagopal; Mark R Contarino; Elisabeth Papazoglou; Irwin Chaiken
Journal:  ChemMedChem       Date:  2011-06-28       Impact factor: 3.466

5.  Peptide Triazole Inactivators of HIV-1 Utilize a Conserved Two-Cavity Binding Site at the Junction of the Inner and Outer Domains of Env gp120.

Authors:  Rachna Aneja; Adel A Rashad; Huiyuan Li; Ramalingam Venkat Kalyana Sundaram; Caitlin Duffy; Lauren D Bailey; Irwin Chaiken
Journal:  J Med Chem       Date:  2015-04-28       Impact factor: 7.446

6.  Antiviral breadth and combination potential of peptide triazole HIV-1 entry inhibitors.

Authors:  Karyn McFadden; Patricia Fletcher; Fiorella Rossi; Muddagowda Umashankara; Vanessa Pirrone; Srivats Rajagopal; Hosahudya Gopi; Fred C Krebs; Julio Martin-Garcia; Robin J Shattock; Irwin Chaiken
Journal:  Antimicrob Agents Chemother       Date:  2011-11-14       Impact factor: 5.191

7.  A model of peptide triazole entry inhibitor binding to HIV-1 gp120 and the mechanism of bridging sheet disruption.

Authors:  Ali Emileh; Ferit Tuzer; Herman Yeh; Muddegowda Umashankara; Diogo R M Moreira; Judith M Lalonde; Carole A Bewley; Cameron F Abrams; Irwin M Chaiken
Journal:  Biochemistry       Date:  2013-03-22       Impact factor: 3.162

8.  Structural determinants for affinity enhancement of a dual antagonist peptide entry inhibitor of human immunodeficiency virus type-1.

Authors:  Hosahudya Gopi; M Umashankara; Vanessa Pirrone; Judith LaLonde; Navid Madani; Ferit Tuzer; Sabine Baxter; Isaac Zentner; Simon Cocklin; Navneet Jawanda; Shendra R Miller; Arne Schön; Jeffrey C Klein; Ernesto Freire; Fred C Krebs; Amos B Smith; Joseph Sodroski; Irwin Chaiken
Journal:  J Med Chem       Date:  2008-04-11       Impact factor: 7.446

9.  Introducing metallocene into a triazole peptide conjugate reduces its off-rate and enhances its affinity and antiviral potency for HIV-1 gp120.

Authors:  Hosahudya Gopi; Simon Cocklin; Vanessa Pirrone; Karyn McFadden; Ferit Tuzer; Isaac Zentner; Sandya Ajith; Sabine Baxter; Navneet Jawanda; Fred C Krebs; Irwin M Chaiken
Journal:  J Mol Recognit       Date:  2009 Mar-Apr       Impact factor: 2.137

10.  Interactions of peptide triazole thiols with Env gp120 induce irreversible breakdown and inactivation of HIV-1 virions.

Authors:  Arangassery Rosemary Bastian; Mark Contarino; Lauren D Bailey; Rachna Aneja; Diogo Rodrigo Magalhaes Moreira; Kevin Freedman; Karyn McFadden; Caitlin Duffy; Ali Emileh; George Leslie; Jeffrey M Jacobson; James A Hoxie; Irwin Chaiken
Journal:  Retrovirology       Date:  2013-12-13       Impact factor: 4.602
View more
  5 in total

1.  Chemical optimization of macrocyclic HIV-1 inactivators for improving potency and increasing the structural diversity at the triazole ring.

Authors:  Adel A Rashad; Kriti Acharya; Ann Haftl; Rachna Aneja; Alexej Dick; Andrew P Holmes; Irwin Chaiken
Journal:  Org Biomol Chem       Date:  2017-09-26       Impact factor: 3.876

2.  Recognition of HIV-inactivating peptide triazoles by the recombinant soluble Env trimer, BG505 SOSIP.664.

Authors:  Kriti Acharya; Adel A Rashad; Francesca Moraca; Per Johan Klasse; John P Moore; Cameron Abrams; Irwin Chaiken
Journal:  Proteins       Date:  2017-03-11

3.  Targeting cell surface HIV-1 Env protein to suppress infectious virus formation.

Authors:  Arangassery Rosemary Bastian; Charles G Ang; Kantharaju Kamanna; Farida Shaheen; Yu-Hung Huang; Karyn McFadden; Caitlin Duffy; Lauren D Bailey; Ramalingam Venkat Kalyana Sundaram; Irwin Chaiken
Journal:  Virus Res       Date:  2017-04-06       Impact factor: 3.303

Review 4.  Therapeutic potential of HIV-1 entry inhibitor peptidomimetics.

Authors:  Nneka Pu Korie; Kwesi Z Tandoh; Samuel K Kwofie; Osbourne Quaye
Journal:  Exp Biol Med (Maywood)       Date:  2021-02-17

5.  Altered Env conformational dynamics as a mechanism of resistance to peptide-triazole HIV-1 inactivators.

Authors:  Shiyu Zhang; Andrew P Holmes; Alexej Dick; Adel A Rashad; Lucía Enríquez Rodríguez; Gabriela A Canziani; Michael J Root; Irwin M Chaiken
Journal:  Retrovirology       Date:  2021-10-09       Impact factor: 3.768
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.